Tekla Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-50,538
| Closed | -$5.42M | – | 185 |
|
|
2023
Q1 | $5.42M | Buy |
50,538
+12,301
| +32% | +$1.32M | 0.21% | 77 |
|
|
2022
Q4 | $4.21M | Buy |
38,237
+6,732
| +21% | +$741K | 0.16% | 82 |
|
|
2022
Q3 | $1.86M | Sell |
31,505
-17,690
| -36% | -$1.04M | 0.08% | 116 |
|
|
2022
Q2 | $1.39M | Buy |
49,195
+27,080
| +122% | +$765K | 0.05% | 125 |
|
|
2022
Q1 | $835K | Buy |
+22,115
| New | +$835K | 0.03% | 150 |
|